Maintaining Drosha expression with Cdk5 inhibitors as a potential therapeutic strategy for early intervention after TBI
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Traumatic brain injury (TBI) is a major cause of death and disability in adults. The pathological process of TBI involves a multifactorial cascade in which kinases have been proven contribute to interactions between relevant factors and amplification of signaling cascades. Cyclin-dependent kinase 5 (Cdk5) is a promising kinase that has been implicated in various brain disorders, including TBI. However, the mechanism by which Cdk5 induces neuronal damage remains unclear. Here, we show for the first time that Drosha, a key enzyme in microRNA biogenesis, is a pivotal substrate of abnormally activated Cdk5. Cdk5-mediated phosphorylation decreases Drosha expression and exacerbates nerve injury in TBI. We proved that maintaining Drosha expression via the administration of repurposed Cdk5 inhibitors that were previously studied in clinical trials is a promising approach for the early treatment of TBI. Together, our work identifies Drosha as a novel target for neuroprotective strategies after TBI and suggests Cdk5-mediated regulation of Drosha expression as a potential therapeutic strategy for early TBI intervention.
Abstract
Traumatic brain injury (TBI) is a major cause of death and disability in adults. The pathological process of TBI involves a multifactorial cascade in which kinases have been proven contribute to interactions between relevant factors and amplification of signaling cascades. Cyclin-dependent kinase 5 (Cdk5) is a promising kinase that has been implicated in various brain disorders, including TBI. However, the mechanism by which Cdk5 induces neuronal damage remains unclear. Here, we show for the first time that Drosha, a key enzyme in microRNA biogenesis, is a pivotal substrate of abnormally activated Cdk5. Cdk5-mediated phosphorylation decreases Drosha expression and exacerbates nerve injury in TBI. We proved that maintaining Drosha expression via the administration of repurposed Cdk5 inhibitors that were previously studied in clinical trials is a promising approach for the early treatment of TBI. Together, our work identifies Drosha as a novel target for neuroprotective strategies after TBI and suggests Cdk5-mediated regulation of Drosha expression as a potential therapeutic strategy for early TBI intervention.
참고문헌 (44)
- Stoica, B. A., "Cell death mechanisms and modulation in traumatic brain injury", Neurotherapeutics : the journal of the American Society for Experi mental NeuroTherapeutics, 7, pp.3~12 (2010)
- Maas, A. I. R., "Traumatic brain injury over the past 20 years : research and clinical progress", Lancet Neurol, 21, pp.768~770 (2022)
- Zweckberger, K., "Effect of early and delayed decompressive craniectomy on secondary brain damage after controlled cortical impact in mice", J. Neurotrauma, 23, pp.1083~1093 (2006)
- Dhavan, R., "A decade of CDK5", Nat. Rev. Mol. Cell Biol, 2, pp.749~759 (2001)
- Asih, P. R., "Functions of p38 MAP kinases in the central nervous system", Front. Mol. Neurosci, 13, pp.570586~ (2020)
- Zhi, L., "CRS induces depression-like behavior after MCAO in rats possibly by activating p38 MAPK", Behav. Brain Res, 437, pp.114104~ (2023)
- Yousuf, M. A., "Involvement of aberrant cyclin-dependent kinase 5", p25activity in experimental traumatic brain injury, 2016, pp.138, 317~327
- Saito, T., "Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators", J. Biol. Chem, 288, pp.32433~32439 (2013)
- Tsai, L. H., "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5", Nature, 371, pp.419~423 (1994)
- Lee, M. S., "Neurotoxicity induces cleavage of p35 to p25 by calpain", Nature, 405, pp.360~364 (2000)
- Roufayel, R., "CDK5 : key regulator of apoptosis and cell survival", Biomedicines, 7, pp.88~ (2019)
- Batra, S., "A review on cyclin-dependent kinase 5 : an emerging drug target for neurodegenerative diseases", Int. J. Biol. Macromol, 230, pp.123259~ (2023)
- Ha, M., "Regulation of microRNA biogenesis", Nat. Rev. Mol. Cell Biol, 15, pp.509~524 (2014)
- Sun, P., "MicroRNA-based ther apeutics in central nervous system injuries", J. Cereb. Blood Flow Metab, 38, pp.1125~1148 (2018)
- Cabrini, M., "DROSHA is recruited to DNA damage sites by the MRN complex to promote non-homologous end joining", J. Cell Sci, 134, pp.jcs249706~ (2021)
- Havens, M. A., "Drosha promotes splicing of a pre microRNA-like alternative exon", PLoS Genet, 10, pp.e1004312~ (2014)
- Lin, Y. T., "Expanding the role of Drosha to the regulation of viral gene expression", Proc. Natl. Acad. Sci. USA, 108, pp.11229~11234 (2011)
- Empl, L., "Selective plasticity of callosal neurons in the adult contralesional cortex following murine traumatic brain injury", Nat. Commun, 13, pp.2659~ (2022)
- Zhang, Y., "PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis", Ann. Rheum. Dis, 79, pp.1227~1233 (2020)
- Hubbard, W. B., "Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury", Brain : a journal of neurology, 144, pp.3788~3807 (2021)
- Wu, J., "Activation of the hedgehog pathway promotes recovery of neuro logical function after traumatic brain injury by protecting the neurovascular unit", Transl. Stroke Res, 11, pp.720~733 (2020)
- Bermpohl, D., "Traumatic brain injury in mice deficient in Bid : effects on histopathology and functional outcome", J. Cereb. Blood Flow Metab, 26, pp.625~633 (2006)
- Mahmood, A., "Effects of treating traumatic brain injury with collagen scaffolds and human bone marrow stromal cells on sprouting of corticospinal tract axons into the denervated side of the spinal cord", J. Neurosurg, 118, pp.381~389 (2013)
- Navarro-Oviedo, M., "MMP10 promotes efficient thrombolysis after ischemic stroke in mice with induced diabetes", Transl. Stroke Res, 10, pp.389~401 (2019)
- Im, D. S., "Cdk5-mediated JIP1 phosphorylation regulates axonal outgrowth through Notch1 inhibition", BMC Biol, 20, pp.115~ (2022)
- Zhou, J., "Cyclin-dependent kinase 5-dependent BAG3 degradation mod ulates synaptic protein turnover", Biol. Psychiatry, 87, pp.756~769 (2020)
- Li, Y., "Inactivated AMPK-α2 promotes the progression of diabetic brain damage by Cdk5 phosphorylation at Thr485 site", Biochimie, 168, pp.277~284 (2020)
- Wang, R., "Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease", Cell Death Dis, 9, pp.693~ (2018)
- Yang, Q., "Stress induces p38 MAPK-mediated phosphorylation and inhibition of Drosha-dependent cell survival", Mol. Cell, 57, pp.721~734 (2015)
- Su, S. C., "Cyclin-dependent kinases in brain development and disease", Annu. Rev. Cell Dev. Biol, 27, pp.465~491 (2011)
- Zhang, M., "CDK inhibitors in cancer therapy, an overview of recent devel opment", Am. J. Cancer Res, 11, pp.1913~1935 (2021)
- Allnutt, A. B., "Physiological and pathological roles of Cdk5 : potential directions for therapeutic targeting in neurodegenerative disease", ACS Chem. Neurosci, 11, pp.1218~1230 (2020)
- Pao, P. C., "Three decades of Cdk5", J. Biomed. Sci, 28, pp.79~ (2021)
- Kwon, S. C., "Structure of human DROSHA", Cell, 164, pp.81~90 (2016)
- Link, S., "Alternative splicing affects the subcellular localization of Drosha", Nucleic Acids Res, 44, pp.5330~5343 (2016)
- Gambichler, T., "Low Drosha protein expression in cutaneous T-cell lym phoma is associated with worse disease outcome", J. Eur. Acad. Dermatol. Venereol, 33, pp.1695~1699 (2019)
- Proshkina, E., "The critical impacts of small RNA biogenesis proteins on aging, longevity and age-related diseases", Ageing Res. Rev, 62, pp.101087~ (2020)
- Xu, H., "p38 MAPK-mediated loss of nuclear RNase III enzyme Drosha underlies amyloid beta-induced neuronal stress in Alzheimer’s disease", Aging cell, 20, pp.e13434~ (2021)
- Do, P. A., "The role of CDK5 in tumours and tumour microenviron ments", Cancers, 13, pp.101~ (2020)
- Meijer, L., "Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials", Acc. Chem. Res, 36, pp.417~425 (2003)
- Shakkour, Z., "Drug repurposing in neurological disorders : Implications for neurotherapy in traumatic brain injury", The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry, 27, pp.620~649 (2021)
- Ghiam, M. K., "Drug repurposing in the treatment of traumatic brain injury", Front. Neurosci, 15, pp.635483~ (2021)
- pyrimidines as CDK2 inhibitors and anti-leukemia, "Bioorg. Chem", 2021, 105431~
- Ardelt, M. A., "Inhibition of cyclin-dependent kinase 5: a strategy to improve sorafenib response in hepatocellular carcinoma therapy", Hepatology(Baltimore, Md. ), 69, pp.376~393 (2019)